Transcriptome from circulating cells suggests dysregulated pathways associated with long-term recurrent events following first-time myocardial infarction.

BACKGROUND Whole-genome gene expression analysis has been successfully utilized to diagnose, prognosticate, and identify potential therapeutic targets for high-risk cardiovascular diseases. However, the feasibility of this approach to identify outcome-related genes and dysregulated pathways following first-time myocardial infarction (AMI) remains unknown and may offer a novel strategy to detect affected expressome networks that predict long-term outcome. METHODS AND RESULTS Whole-genome expression microarray on blood samples from normal cardiac function controls (n=21) and first-time AMI patients (n=31) within 48-hours post-MI revealed expected differential gene expression profiles enriched for inflammation and immune-response pathways. To determine molecular signatures at the time of AMI associated with long-term outcomes, transcriptional profiles from sub-groups of AMI patients with (n=5) or without (n=22) any recurrent events over an 18-month follow-up were compared. This analysis identified 559 differentially-expressed genes. Bioinformatic analysis of this differential gene-set for associated pathways revealed 1) increasing disease severity in AMI patients is associated with a decreased expression of genes involved in the developmental epithelial-to-mesenchymal transition pathway, and 2) modulation of cholesterol transport genes that include ABCA1, CETP, APOA1, and LDLR is associated with clinical outcome. CONCLUSION Differentially regulated genes and modulated pathways were identified that were associated with recurrent cardiovascular outcomes in first-time AMI patients. This cell-based approach for risk stratification in AMI could represent a novel, non-invasive platform to anticipate modifiable pathways and therapeutic targets to optimize long-term outcome for AMI patients and warrants further study to determine the role of metabolic remodeling and regenerative processes required for optimal outcomes.

[1]  T. Speed,et al.  Summaries of Affymetrix GeneChip probe level data. , 2003, Nucleic acids research.

[2]  Rafael A Irizarry,et al.  Gene expression in giant cell myocarditis: Altered expression of immune response genes. , 2005, International journal of cardiology.

[3]  J. Zweier,et al.  Transcriptome analysis of the ischemia-reperfused remodeling myocardium: temporal changes in inflammation and extracellular matrix. , 2006, Physiological genomics.

[4]  B. Nordestgaard,et al.  Genetic inhibition of CETP, ischemic vascular disease and mortality, and possible adverse effects. , 2012, Journal of the American College of Cardiology.

[5]  Terence P. Speed,et al.  Quality Assessment for Short Oligonucleotide Microarray Data , 2007, Technometrics.

[6]  Xueli Yuan,et al.  Endothelial-to-mesenchymal transition contributes to cardiac fibrosis , 2007, Nature Medicine.

[7]  M. Capogrossi,et al.  The epicardium in cardiac repair: from the stem cell view. , 2011, Pharmacology & therapeutics.

[8]  M. Law,et al.  The underlying risk of death after myocardial infarction in the absence of treatment. , 2002, Archives of internal medicine.

[9]  Rafael A. Irizarry,et al.  Bioinformatics and Computational Biology Solutions using R and Bioconductor , 2005 .

[10]  Jun Ma,et al.  The peripheral blood transcriptome dynamically reflects system wide biology: a potential diagnostic tool. , 2006, The Journal of laboratory and clinical medicine.

[11]  Leah B. Honor,et al.  Adult mouse epicardium modulates myocardial injury by secreting paracrine factors. , 2011, The Journal of clinical investigation.

[12]  V. Fuster,et al.  Epithelial-to-Mesenchymal and Endothelial-to-Mesenchymal Transition: From Cardiovascular Development to Disease , 2012, Circulation.

[13]  D. Rader,et al.  Macrophage reverse cholesterol transport: key to the regression of atherosclerosis? , 2006, Circulation.

[14]  F. Azuaje,et al.  Transforming growth factor β receptor 1 is a new candidate prognostic biomarker after acute myocardial infarction , 2011, BMC Medical Genomics.

[15]  G. Parmigiani,et al.  Identification of a Gene Expression Profile That Differentiates Between Ischemic and Nonischemic Cardiomyopathy , 2004, Circulation.

[16]  Thomas J. Wang,et al.  The search for new cardiovascular biomarkers , 2008, Nature.

[17]  Jean YH Yang,et al.  Bioconductor: open software development for computational biology and bioinformatics , 2004, Genome Biology.

[18]  Raghu Kalluri,et al.  The basics of epithelial-mesenchymal transition. , 2009, The Journal of clinical investigation.

[19]  Joshua M. Hare,et al.  Transcriptomic Biomarkers for Individual Risk Assessment in New-Onset Heart Failure , 2008, Circulation.

[20]  Gordon K. Smyth,et al.  limma: Linear Models for Microarray Data , 2005 .

[21]  Jan Komorowski,et al.  Aetiology‐specific patterns in end‐stage heart failure patients identified by functional annotation and classification of microarray data , 2006, European journal of heart failure.

[22]  E. Antman,et al.  The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. , 2000, JAMA.

[23]  Á. Avezum,et al.  Predictors of hospital mortality in the global registry of acute coronary events. , 2003, Archives of internal medicine.

[24]  P. Reitsma,et al.  High throughput mRNA profiling highlights associations between myocardial infarction and aberrant expression of inflammatory molecules in blood cells. , 2005, Blood.

[25]  R. Irizarry,et al.  Gene expression analysis of ischemic and nonischemic cardiomyopathy: shared and distinct genes in the development of heart failure. , 2005, Physiological genomics.

[26]  Thomas J. Wang,et al.  Identifying novel biomarkers for cardiovascular disease risk prediction , 2012, Journal of internal medicine.

[27]  Mark D. Huffman,et al.  Heart disease and stroke statistics--2013 update: a report from the American Heart Association. , 2013, Circulation.

[28]  Thomas P Cappola,et al.  Transcriptomic biomarkers of cardiovascular disease. , 2012, Progress in cardiovascular diseases.

[29]  Ben Bolstad,et al.  Low-level Analysis of High-density Oligonucleotide Array Data: Background, Normalization and Summarization , 2003 .

[30]  Gordon K Smyth,et al.  Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments , 2004, Statistical applications in genetics and molecular biology.

[31]  J. Mcneish,et al.  The Correlation of ATP-binding Cassette 1 mRNA Levels with Cholesterol Efflux from Various Cell Lines* , 2000, The Journal of Biological Chemistry.

[32]  Benjamin M. Bolstad,et al.  affy - analysis of Affymetrix GeneChip data at the probe level , 2004, Bioinform..

[33]  J. Davis.  Bioinformatics and Computational Biology Solutions Using R and Bioconductor , 2007 .

[34]  Monocyte/macrophage expression of ABCA1 has minimal contribution to plasma HDL levels. , 2001 .

[35]  O. Francone,et al.  Monocyte/macrophage expression of ABCA1 has minimal contribution to plasma HDL levels. , 2001, The Journal of clinical investigation.

[36]  L. Stanton,et al.  Altered patterns of gene expression in response to myocardial infarction. , 2000, Circulation research.

[37]  John D. Storey,et al.  A network-based analysis of systemic inflammation in humans , 2005, Nature.

[38]  R. Gentleman,et al.  Independent filtering increases detection power for high-throughput experiments , 2010, Proceedings of the National Academy of Sciences.